CA
DYN icon

CoreCap Advisors’s Dyne Therapeutics DYN Stock Holding History

CoreCap Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47
Closed -$492 – 2905
2025
Q1 		$492 Buy
47
+40
+571% +$572 ﹤0.01% 2689
2024
Q4 		$165 Buy
+7
New +$207 ﹤0.01% 2741

Other funds holding DYN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CoreCap Advisors's DYN Position: Q2 2025 in Review

CoreCap Advisors sold out of Dyne Therapeutics (DYN) in Q2 2025, closing a stake of 47 shares — an estimated $492 sold.

CoreCap Advisors first reported a position in DYN in Q4 2024 and held it in 2 quarters. The position peaked at $492 in Q1 2025. 197 funds tracked by Wall St. Rank hold DYN as of Q2 2025.

  • CoreCap Advisors reported no remaining Dyne Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 47 Dyne Therapeutics shares in Q2 2025, an estimated $492.
  • CoreCap Advisors first reported a position in Dyne Therapeutics in Q4 2024 and held it in 2 quarters.
  • CoreCap Advisors's Dyne Therapeutics position peaked at $492 in Q1 2025.
  • 197 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.